Background: Investigators may elect to extend follow-up of participants enrolled in a randomized clinical trial after the trial comes to its planned end. The additional follow-up may be initiated to learn about longer term effects of treatments, including adverse events, costs related to treatment, or for reasons unrelated to treatment such as to observe the natural course of the disease using the established cohort from the trial. Purpose: We examine transitioning from trials to extended follow-up studies when the goal of additional follow-up is to observe longer term treatment effects. Methods: We conducted a literature search in selected journals from 2000 to 2012 to identify trials that extended follow-up for the purpose of studying longer term treatment effects and extracted information on the operational and logistical issues in the transition. We also draw experience from three trials coordinated by the Johns Hopkins Coordinating Centers that made transitions to extended follow-up: the Alzheimer's Disease Anti-inflammatory Prevention Trial, Multicenter Uveitis Steroid Treatment trial, and Childhood Asthma Management Program. Results: Transitions are not uncommon in multicenter clinical trials, even in trials that continued to the planned end of the trial. Transitioning usually necessitates new participant consents. If study infrastructure is not maintained during the transition, participants will be lost and re-establishing the staff and facilities will be costly. Merging data from the trial and follow-up study can be complicated by changes in data collection measures and schedules. Limitations: Our discussion and recommendations are limited to issues that we have experienced in transitions from trials to follow-up studies. Discussion: We discuss issues such as maintaining funding, institutional review board and consent requirements, contacting participants, and combining data from the trial and follow-up phases. We conclude with a list of recommendations to facilitate transitions from a trial to an extended follow-up study.
Introduction
Trials are dynamic organisms. Their form or character can change while underway as a result of protocol revisions, for example, as with the addition or deletion of a study treatment or change in dosage schedule of a treatment, and such changes may prompt investigators to decide to extend follow-up of participants after the trial period of the study ends. Alternatively, the prompt for additional follow-up of a trial's participants may derive from events or research subsequent to termination of the trial. Thus, transitions may be seamless, with participants moving to follow-up as the trial ends or may take place months or years after the trial has finished, for example, as in mortality follow-up of letter, or without any direct contact (e.g. in the case of mortality follow-up via death indices).
Factors causing investigators and sponsors to transition from trial to follow-up include interest in the longterm effects of treatments administered in the trial, characterizing disease progression in persons studied in the trial, characterizing frequency of adverse events after cessation of the trial, or characterizing mortality following cessation of the trial. The likelihood of transition to follow-up depends on identifying a worthwhile scientific question that can be answered by additional follow-up, a sponsor or funder willing to pay for the follow-up, investigators willing to do the follow-up, feasibility of locating and collecting data on persons enrolled in the trial and their willingness to continue, and size and uniqueness of the original study population.
Although many trials extend follow-up after the trial period ends, not much has been written about the issues that are encountered. We have experienced transitioning in three trials coordinated by the Johns Hopkins Coordinating Center, and our goal is to review related transitions in the literature and to comment on our own experience.
Methods
Identifying trials from literature search of selected journals and personal experience, we describe trials that have transitioned to extended follow-up with the primary goal of comparing long-term treatment effects.
Literature search
We searched PubMed for articles from the New England Journal of Medicine, BMJ, Journal of the American Medical Association, Lancet, and Annals of Internal Medicine with publication dates between 2000 and 2012 and reporting on recent multicenter trials that have undergone this transition. The search was not meant to be representative of all literature published but to provide insight into issues encountered during transitions and strategies for resolution. The search targeted publications including any of the following terms (the search strategy is detailed in Appendix 1):
Additional follow-up; Continuation study; Extended follow-up; Extended observational period; Legacy; Long-term effect; Post-trial; Follow-up study.
Articles identified by the aforementioned search terms (as of 04 April 2013) were then reviewed (A.S.C. with review of questionable results by L.T.D.) to determine whether the results reported were from follow-up of a previously identified population enrolled and followed in a clinical trial. To limit the results to those transitions that were similar to our experience, we included only those trials and follow-up studies meeting the criteria shown in Table 1 .
Trials conducted at Johns Hopkins Coordinating Centers
At the Johns Hopkins Coordinating Centers, several trials have transitioned to extended follow-up. We examine three trials that transitioned to extended follow-up in order to compare long-term treatment effects by the original treatment groups: Alzheimer's Disease Anti-inflammatory Prevention Trial (ADAPT) to ADAPT Follow-up Study (ADAPT-FS), Multicenter Uveitis Steroid Treatment (MUST) trial to MUST Follow-up Study (MUST-FS), and Childhood Asthma Management Program (CAMP) to CAMP Continuation Studies (CAMPCS). The study protocols were reviewed and approved by the ethics committee at each clinical center and the coordinating center for these trials and follow-up studies.
ADAPT and ADAPT-FS. The ADAPT was designed to address whether non-steroidal anti-inflammatory drugs can prevent or delay the onset of Alzheimer's disease. 3 It was a randomized, 4 ADAPT follow-up of participants off treatment continued through the end of February 2007 (mean followup of 3.2 years). Patients and investigators were unmasked to treatment assignment from May to July of 2007 prior to the cessation of funding for clinics in the fall of 2007. An analysis of the ADAPT trial suggested that the effects of naproxen on the incidence of Alzheimer's disease changed over time, with an increase in risk observed in approximately the first 2 years after randomization with a decreasing risk thereafter. 5 Given the lack of available trial data on the long-term effects of non-steroidal anti-inflammatory drugs on cognitive function, the investigators judged it necessary to extend follow-up of the cohort to learn whether the emerging trends in effects on incident Alzheimer's disease continued. Funding for additional follow-up was obtained in the second half of 2009, and participants in ADAPT were re-contacted in 2010 for participation in ADAPT-FS.
Ultimately 1537 people were enrolled for extended cognitive follow-up in ADAPT-FS, 6 and record of death was obtained though death searches for an additional 134 participants. Follow-up in ADAPT-FS was completed at the same clinical centers where ADAPT was completed. Figure 1 The MUST Trial was designed to provide at least 2 years of follow-up on participants and MUST Trial 2year results have been published. 8 The two treatments produced similar improvements in visual acuity. There were fewer participants experiencing uveitis activity and more reported improvement in vision-related quality of life in the implant group but also a higher incidence of ocular complications such as cataract and glaucoma. 8 Because intermediate, posterior, or panuveitis is usually a chronic disease and the implants were designed to last 2.5-3 years, the investigators felt that continued followup of the MUST cohort would provide data on longterm treatment effectiveness and safety.
In MUST-FS, participants from the MUST Trial are being followed for 5 additional years and are encouraged to continue with their MUST Trial assigned treatments for uveitis control. Investigators used funds from the MUST Trial to fund the transition from MUST Trial to MUST-FS. There was no lapse in funding between MUST Trial and MUST-FS. MUST-FS enrolled 215 participants from MUST Trial. The data collection schedule changed from every 3 months in the trial to every 6 months in MUST-FS, which introduced challenges for data merging and analysis. Figure 2 displays the timeline for MUST Trial and MUST-FS.
CAMP and CAMPCS. The CAMP was a randomized, double-masked, placebo-controlled trial conducted at eight North American clinical centers comparing the efficacy and safety of 400 mg/day of budesonide, 16 mg/day of nedocromil, and matching placebo in children with mild-to-moderate asthma. 9 CAMP was funded by the National Heart, Lung, and Blood Institute. A total of 1041 children aged 5-12 years were randomized to treatment between December 1993 and September 1995 and followed for a mean of 4.3 years. 10 The CAMP results showed that neither budesonide nor nedocromil were superior to placebo with respect to lung function but that budesonide improved airway responsiveness and asthma control. However, children in the budesonide group had a small reduction in mean height compared to the other two groups at the end of the trial. 10 The CAMP investigators wanted to continue to follow-up the children to see whether the years of treatment in CAMP had any lasting effect on asthma control or height at adulthood after discontinuation.
A study medication washout phase was completed in March through October 1999. Children continued to use asthma medications prescribed in supplement to CAMP study medication. Beginning in November 1999, participants were enrolled into the CAMPCS during which the children's asthma was managed by their asthma care provider and the asthma medications prescribed could include the study medications (budesonide and nedocromil) which had been approved by the Food and Drug Administration (FDA) during the trial.
Follow-up under CAMPCS continued from November 1999 through March 2012, in three funding phases. Each phase included at least one annual inperson visit at the CAMP clinical centers. 11, 12 More than 85% of the original CAMP enrollees continued in at least one of the follow-up study phases, and 80% participated in all three of the follow-up phases. Figure 3 displays the timeline for CAMP and CAMPCS.
Results

Literature search
A total of 345 articles were identified with the PubMed search criteria. In all, 17 trials (16 corresponding follow-up studies) met our inclusion criteria for this discussion; the Observational follow-up of the Trials of Hypertension Prevention (TOHP) follow-up study enrolled participants from two trials (TOHP I and II). Table 2 gives details regarding the extended follow-up studies.
Of the 17 trials, 12 had primary or secondary prevention outcomes and included healthy participants or individuals with certain risk factors for a specific disease or condition: Women's Health Initiative Hormone Therapy Trial 13 and Heart Protection Study 14 for prevention of cardiovascular events; United Kingdom Prospective Diabetes Study, 15 Diabetes Control and Complications Trial, 16 Finnish Diabetes Prevention Study, 17 
and the China Da Qin Diabetes Prevention Study 18 for prevention of complications of diabetes;
Overview of the Role of Antibiotics in Curtailing Labour and Early delivery I 19 and Overview of the Role of Antibiotics in Curtailing Labour and Early delivery II 20 for prevention of adverse neonatal outcomes with preterm rupture of membranes or preterm labor; TOHP I 21 and II 22 for prevention of hypertension; Diabetes Prevention Program for prevention of type 2 diabetes; 23 and Long-Term Intervention with Pravastatin in Ischemic Disease for the prevention of cardiovascular events and mortality. 24 The remaining five trials were treatment trials: CAMP compared treatments for childhood asthma, 9 a trial of treatment strategies for postnatal urinary and fecal incontinence, 25 Multicenter Study of Hydroxyurea in Sickle Cell Anemia compared treatments for sickle cell anemia, 26 a trial comparing medical and surgical therapies for gastroesophageal reflux disease, 27 and a trial testing fatty acid supplementation in infant formula. 28 Eight of the trials corresponding to the follow-up studies in Table 2 consisted of only drug interventions, 9, 14, 16, 19, 20, 24, 26, 28 five consisted of only behavioral interventions, 17, 18, 21, 22, 25 three were a combination of both drug and behavioral interventions, 13, 15, 23 and one compared drug and surgery interventions. 27 No trials of devices or biologics met our criteria for inclusion mostly because we required repeated treatment administration for inclusion. Most of the trials were primarily funded by government resources, 9, [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] one was funded mainly by a non-profit research center, 25 and two were funded by an industry funder; 24,28 some trials had multiple funding sources. The average length of follow-up time during the original trials is between 3 and 4 years.
In all, 13 trials continued all treatment arms to their planned end. In the Women's Health Initiative Hormone Therapy Trial, the estrogen plus progestin arm was stopped in 2002, 29 and the estrogen alone arm was stopped in 2004, 30 because of evidence that the overall risk to participants' health exceeded the benefit of the hormone therapy. In the Finnish Diabetes Prevention Study, the Endpoint Committee recommended ending the trial ahead of schedule because the interim analysis conducted in March 2000 showed that the cumulative incidence of diabetes was significantly lower in the lifestyle intervention than the control group. 31, 32 The blinded treatment phase of the Diabetes Prevention Program was stopped a year before the planned end because the superiority of both the lifestyle intervention and metformin was established. 33 The Long-Term Intervention with Pravastatin in Ischemic Disease trial was also terminated early with evidence of survival benefits. 34 The purpose of each extended follow-up study listed in Table 2 was to gather information on the long-term effects of the treatments that might have appeared after the trial ended, including duration of any effects observed during the treatment period, emergence of new effects, and waning or intensification of effects. During the extended follow-up periods, there was no additional randomization to treatment and participants might receive standard of care treatment, continue on their study treatment under open label, non-study prescription, or receive no treatment at all, depending on their own preference or need and their primary care provider's judgment. Eight studies had periods of time or gaps between the close of the original trial and initiation of extended follow-up; [35] [36] [37] [38] [39] [40] [41] [42] [43] these gaps ranged from 2 36,37 to 10 years. 39 During the follow-up study, the data collection responsibilities appear to have shifted to a central facility (coordinating center) instead of the original recruiting centers in five of the studies, [36] [37] [38] [39] [40] 44 with the follow-up primarily conducted through mailed questionnaires and/or telephone contacts. The recruiting clinics continued to perform data collection at inperson visits for the remaining follow-up studies. 10, 32, 34, 35, [41] [42] [43] [45] [46] [47] [48] Issues encountered in ADAPT, MUST, and CAMP transitions Obtaining funding. Given the huge investment made in the original trial, funders frequently have an interest in repurposing the trial's resources (investigators, participants, and infrastructure) to obtain additional results and hence may have an interest in supporting a followup study of the trial participants. But at times, the desire or resources from the original funder have disappeared and investigators must find funds elsewhere. In ADAPT, early attempts to obtain funds for additional follow-up from the National Institute on Aging were unsuccessful. The investigators then sought and received funding from a non-profit organization for the follow-up data collection. Eventually, additional funding was also received from the National Institute on Aging through the American Recovery and Reinvestment Act. When funding is provided, it is frequently reduced relative to the trial level. In ADAPT-FS, funding reductions required a change in data collection methods so that regular visits to assess cognition were conducted over the phone and in-person visits only occurred when a participant triggered a more thorough dementia examination. The funding for MUST-FS was less than half of MUST Trial funding resulting in fewer study visits (every 6 months instead of 3 months) and a sharp reduction in ancillary testing. Funding for the CAMP Continuation Study phases was reduced compared to the trial phase. The CAMPCS visit schedule included fewer in-person visits per year, the patient education center established for the CAMP trial was not continued in the follow-up phase, and the frequency of some clinical assessments was decreased in the follow-up phase (e.g. home dust collection was not completed in the follow-up phase and psychological assessments were more limited in the follow-up phase). Staffing levels in the extended phases for ADAPT, MUST, and CAMP were reduced compared to the trial phases, in accordance with these changes and reductions in study activities. While some loss of staff with experience and knowledge of the trials was experienced by each study, the effects were mitigated by reassigning staff where possible to other studies being conducted within the research group so that staff were available, when needed, for the follow-up studies.
Transition period. The period of transition between the trial and the follow-up study might be seamless in that participants exit the trial and enter the follow-up study without any gap in their contact schedule, whereas other transitions involve periods of time during which the trial has closed and the follow-up study has not opened. The MUST research group was able to design the follow-up study and obtain funding so that the original cohort could be followed without interruption. During this transition period between the MUST Trial and MUST-FS, participants at some clinical centers were followed under the MUST Trial protocol for a longer period of time than others while institutional review board (IRB) approval for the MUST-FS was obtained. The study website, forms, and data entry systems had to accommodate both MUST Trial and MUST-FS data collection requirements simultaneously. The CAMP research group was similarly able to obtain funding to transition seamlessly from trial to follow-up without interruption.
In ADAPT, funding for the trial ended before funding could be secured for continued follow-up so participants had to be closed out of the trial. The lapse introduced multiple difficulties and inefficiencies: establishing a new infrastructure, hiring and training new staff due to turn-over during the lapse, submitting new protocols through IRBs, and finding participants who had been out of contact with study staff.
Consent. The first issue related to consent in follow-up studies is whether re-consent for the additional followup is necessary. Most IRBs require specific language about how long participants will be asked to participate and who will contact them, making it unlikely that the consent for the trial will be adequate for the additional follow-up. If language in the original consent was not specific about follow-up time, then it might be sufficient for the extended follow-up. Follow-up for vital status via searches of the National Death Index or Social Security Death Master File may be possible without additional permission from the patient.
Changes in study organization, protocol, or procedures that occur between the trial and follow-up will likely mandate re-consent. We had to consent participants for the ADAPT-FS, MUST-FS, and CAMPCS because the trial consents were specific to the trial's goals, follow-up period, methods of contact, visit schedules, and treatment, and were deemed not to cover the purpose, procedures, and so on of the additional follow-up.
In ADAPT-FS, the coordinating center prepared a letter that clinic staff mailed to the last known address of each participant; the letters explained the rationale and methods of the follow-up study, informed the participants that they would be contacted by phone soon, and provided clinic contact information in case of questions before the telephone call. During the telephone contact, coordinators reiterated information about the follow-up study and asked the participant whether he or she would be willing to do a telephone cognitive assessment (oral consent) and make an in-person visit, if necessary, to the clinical center. If an in-person visit was triggered due to cognitive difficulties detected during the telephone assessment, the patient was asked to schedule a clinic visit. A more detailed and written consent was collected at that visit.
An option that can ease the transition but will require IRBs approvals is to create a file collecting participant contact information at a central facility such as the coordinating center before the trial ends. Creation of the file will not be possible if the trials consents state that participants' names and addresses will not be transmitted to the coordinating center or other central facility. Absent such a central file, the only possible route of contact with participants is via study clinical centers. Even when the trial is ongoing, the absence of an identifier file in the coordinating center may be problematic. For example, that absence meant that the coordinating center in ADAPT could not assist clinics in preparing mailings to participants during the close of ADAPT to inform them of treatment assignment. Likewise, mortality sweeps at the end of ADAPT-FS using the National Death Index or Social Security Death Master File had to be done at the clinical centers. Once a trial has finished and the investigator group has disbanded, there is no viable means for mortality follow-up without a central file of identifiers.
Finding study participants. The ADAPT-FS, MUST-FS, and CAMPCS investigators attempted to follow as many of the trial participants as possible and did not allow enrollment of non-trial participants in their follow-up phases. There are other models of transitioning that will not be discussed such as one where a trial ends and extended follow-up begins with a combination of trial participants and new participants not involved in a trial (e.g. the Longitudinal Studies of the Ocular Complications of Acquired Immunodeficiency Syndrome). 49 If there is a lapse in funding between the trial and the follow-up, like in ADAPT, re-contacting participants becomes more difficult. In ADAPT-FS, personal identification, including addresses, was stored only at the clinical sites, so follow-up could not be performed centrally by the coordinating center. Follow-up was performed instead at the original clinical centers starting with the distribution of an introductory letter. After the letter, study staff attempted to contact participants at the last known address recorded during ADAPT. If not successful in contacting the participant, clinical center staff would attempt to call the participant's collateral respondent, friend, or family members listed in ADAPT records and, if necessary, check current telephone directory for listings both for the participant and the participant's contacts. Participants who were contacted were asked to provide an assessment over the phone, and if they agreed, they were enrolled in ADAPT-FS. Staff from the clinical centers performed death searches to determine vital status for all ADAPT participants who were not contacted for ADAPT-FS, which included those who were eligible and could not be found (n = 302), but also those who refused further contact during ADAPT (n = 65) and those who were diagnosed with dementia during ADAPT (an additional n = 66).
For seamless transitions between trial and follow-up studies, participants can be asked at a trial or transition visit or contact whether they would be willing to continue extended follow-up. For example in MUST, a letter was mailed to trial participants prior to the start of the final round of trials visits explaining the impending transition to follow-up. An additional letter was sent subsequently to inform participants of the MUST trial results with instructions to contact study staff to discuss the results. At the next MUST visit, the participants willing to continue in MUST-FS were consented and scheduled for their first MUST-FS visit.
In CAMP, consent was obtained at the start of each new phase of follow-up. At the last visit of each phase, coordinators spoke with parents and participants about the planned next phase of follow-up, either obtaining consent for the new phase (if logistics permitted) or providing written material about the new phase and obtaining permission to contact the family (or participant if the participant had reached the age of consent) once the new phase had opened. At the start of the trial, CAMP participants were aged 5-12 years and consent was provided by the parent or guardian. Starting with the first follow-up continuation phase, CAMPCS participants began to reach the age of consent and were asked to provide consent to the followup. CAMPCS continued long enough so that all of the participants had entered adulthood by the start of the third continuation phase. Investigators discovered that interest or disinterest in participation was not static. Teens or college students might not be interested, but young adults who were on their own or were new parents often rekindled their interest in CAMP. At the end of the trial, participants were provided with a personalized summary of their own measurements and test results over the duration of the trial; during the continuation phases, brief updates on CAMP contributions to asthma care were provided to reinforce the bond with CAMP.
Outcome measures. The outcome measures of the follow-up phase depend on the goal of continued follow-up. Care should be taken to make sure outcomes are collected in such a way that the data from the trial and follow-up study can be combined. This is easier said than done when there is pressure to ''improve'' the data collection because of changes in technology of measurement from the time of the trial to follow-up. Minor wording changes in data items common to the trial and follow-up may make comparison across the two components of study problematic.
In ADAPT, an analysis of treatment effects over time suggested that the naproxen treated group had an increased risk of Alzheimer's disease early in the trial (compared to placebo) and a decreased risk in the late years of the trial. The goal of the follow-up was to see whether the decreased risk observed late in the trial was sustained.
If there is a gap between the trial and the follow-up study, this can create problems for timing survival outcomes. For example, Alzheimer's disease diagnoses that occurred during the period between ADAPT and ADAPT-FS had to be confirmed during ADAPT-FS. As such, the study events for the survival analysis identified during ADAPT-FS had a short window of possible event dates when in reality, the diagnosis dates should have been spread over the several years gap between the ADAPT and ADAPT-FS. This makes it difficult to summarize denominators for presentation and complicates calculation of incidence rates.
In MUST, the primary trial outcome of change in visual acuity from baseline to 2 years was very similar in the two uveitis treatment strategies, and the followup study was designed to continue to collect data on the primary outcome as well as information on long-term safety and treatment costs. The data collection interval changed from 3 to 6 months, which caused difficulties in combining some of the outcomes from the trial and follow-up study. The trial results were published with estimates of several outcomes based on a 3-month visit schedule. An analysis testing different intervals (3 vs 6 months) for statistical analyses of trial data were necessary before combining the trial and follow-up data.
The original CAMP study was designed to compare efficacy of three management strategies for childhood asthma, while the follow-up was designed primarily to assess long-term effects of the inhaled corticosteroid treatment, both with regard to lung function and potential negative effects on attained adult height. The last two phases of CAMP follow-up were also designed to address the natural history of mild to moderate childhood asthma which requires different analysis strategies for timing of study events (e.g. timed by age of the child instead of time since randomization). During the CAMP trial, the timeline of interest for analysis of the outcomes was the duration since randomization. In the follow-up studies, the enrollment was spread over a number of years. The visits being completed in a calendar time period represented different durations from randomization. Sensitivity analysis using age as the timeline was a valuable approach during the follow-up studies.
Treatment during extended follow-up study. In ADAPT-FS, the investigators had no reason to offer any of the ADAPT treatments to the participants who continued follow-up since neither of the experimental treatments were found to be effective. MUST found that both treatment strategies provided similar improvements on the primary outcome of visual acuity and most participants experienced good control of uveitis flares. Therefore, investigators are encouraged but not required to continue to provide treatment according to randomized assignment in MUST-FS. At the end of the CAMP trial, participants returned to their personal asthma care provider for asthma treatment per clinical guidelines; CAMP study physicians sent the provider their recommendations if permitted by the participant.
Limitations
Other issues could arise with transitioning that we did not encounter. Our experiences with ADAPT, MUST, and CAMP may not be generalizable to all trials transitioning to extended follow-up because CAMP and ADAPT were trials in populations for whom it may be markedly difficult to continue follow-up (i.e. children and older adults) and our experience focuses on trials conducted primarily in the United States. In addition, other types of transitions, such as those where the investigators enroll new participants during the follow-up period, those that only follow a subset of originally enrolled participants, or those that collect data only through registries (no participant contact), will have other issues not covered here.
Discussion
It is not uncommon for trials to transition to an extended follow-up period. This transition occurs in prevention and treatment trials, trials enrolling children and adults, trials funded from many sources, and those testing a variety of interventions. The reality is that transitions from trial to follow-up study are usually after thoughts. That being so, investigators can expect to face a variety of problems and issues if they elect to engage in some form of follow-up after the trial is finished. In Table 3 , we have included some recommendations on how to make extended follow-up more feasible based on our experience from ADAPT, MUST, and CAMP.
Our primary recommendation is to plan ahead. Just as good design includes features to protect against Type I error, deviations from assigned treatment, loss to follow-up of participants, so might the trial designer build in some insurance in case the trial results leave an important question dangling. Consider designing a consent that leaves the door open to further contact, try to use data collection procedures that will work in the future, and always think about what should be done now to ensure the most options later. Table 3 . Recommendations for making extended follow-up of trials more feasible. 1 Recognize that the desire of investigators to transition to follow-up usually does not emerge until the trial is near the end or after it has ended and design and plan for the possibility. If there is to be a seamless transition to follow-up, funding for follow-up has to be secured when the trial winds down. For that to happen, funding applications have to be submitted in time for completion of the review, award, and possible re-submission and re-review periods to be completed before funding for the trial ends. 2 Help established clinical centers maintain the study infrastructure as long after close of the trial as possible.
Once the infrastructure is gone, the chance of any form of active follow-up markedly diminishes. 3 Ask study clinics to maintain IRB or ethics approvals after the close of the trial. Follow-up involving contact will likely require new consents. It is less labor intensive to obtain approvals for follow-up if submitted as amendments to existing approvals than it is to prepare new proposals. However, some IRBs charge a fee for reviewing yearly renewals; if funding lapses, continuing IRB approvals at all clinics may not be possible. 4 Inform study participants, on departure from trials, that they may be contacted later and locator information should be updated on departure; this is prudent even if there is no plan to transition to follow-up when people depart. 5
Commission the coordinating center to assemble a central file of names, addresses, and other locator information for persons in the trial on close of the trial. Obtain IRB approval and participant consent for such collection early in the course of the trial. The ability to re-contact is important in any trial where there is possibility of late term treatment effects. Even mortality follow-up, such as in the Coronary Drug Project or Multiple Risk Factor Intervention Trial, is precluded once clinics are closed without a central file of names and addresses. 6 Design data collection schedules and forms or screens in the follow-up study with merging the trial and followup data in mind. Minimize differences in the data collection methodology 7
Minimize the time between the trial and follow-up study. The number of people who can be contacted and who are willing to resume follow-up after from the end of the trial will diminish as the time between contacts increases. 8
Continue to attempt to contact participants who might have previously been too busy or uninterested in continued participation in the trial or earlier stages of the follow-up study (unless the participant explicitly said not to contact him or her again). In trials of children or in trials of participants who are also going through a transition phase in their life, interest in participation will likely wax or wane with time.
IRB: institutional review board.
